Thanh-Trang T Vo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1763067/publications.pdf

Version: 2024-02-01

1039406 1281420 12 567 9 11 citations h-index g-index papers 12 12 12 1318 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models. Blood, 2021, 137, 3365-3377.	0.6	47
2	Targeting elF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition. Scientific Reports, 2021, 11, 21689.	1.6	2
3	Statins enhance efficacy of venetoclax in blood cancers. Science Translational Medicine, 2018, 10, .	5.8	61
4	mTOR inhibition enhances efficacy of dasatinib in <i>ABL</i> -rearranged Ph-like B-ALL. Oncotarget, 2018, 9, 6562-6571.	0.8	15
5	Targeting mTOR for the treatment of B cell malignancies. British Journal of Clinical Pharmacology, 2016, 82, 1213-1228.	1.1	36
6	mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL. Blood, 2016, 128, 2763-2763.	0.6	5
7	Statins Potentiate the Cytotoxic Effect of ABT-199 in Diffuse Large B Cell Lymphoma. Blood, 2016, 128, 3969-3969.	0.6	O
8	MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget, 2015, 6, 35202-35217.	0.8	23
9	mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. Oncotarget, 2015, 6, 2088-2100.	0.8	30
10	INPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency. Cancer Discovery, 2015, 5, 697-700.	7.7	17
11	Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML. Cell, 2012, 151, 344-355.	13.5	294
12	BH3-Only Proteins and Their Effects on Cancer. Advances in Experimental Medicine and Biology, 2010, 687, 49-63.	0.8	37